<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Antimetabolites; Methotrexate: malignant disease; Methotrexate: malignant disease; Leukaemia: acute: lymphoblastic; Choriocarcinoma; Leukaemia: CNS, prophylaxis; Meningeal carcinoma; Methotrexate: malignant disease; Capecitabine; Cytarabine; Fludarabine; Leukaemia: chronic lymphocytic; CLL see Leukaemia, chronic lymphocytic; Cladribine; Clofarabine; Leukaemia: acute; Nelarabine; Gemcitabine; Fluorouracil: malignant disease; Pemetrexed; Raltitrexed; Mercaptopurine: malignant disease; Tegafur; Tioguanine; Thioguanine see Tioguanine; Azacitidine; Decitabine" /><meta name="IX" content="Antimetabolites; Methotrexate: malignant disease; Methotrexate: malignant disease; Leukaemia: acute: lymphoblastic; Choriocarcinoma; Leukaemia: CNS, prophylaxis; Meningeal carcinoma; Methotrexate: malignant disease; Capecitabine; Cytarabine; Fludarabine; Leukaemia: chronic lymphocytic; Cladribine; Clofarabine; Leukaemia: acute; Nelarabine; Gemcitabine; Fluorouracil: malignant disease; Pemetrexed; Raltitrexed; Mercaptopurine: malignant disease; Tegafur; Tioguanine; Azacitidine; Decitabine" /><meta name="IXN" content="CLL see Leukaemia, chronic lymphocytic; Thioguanine see Tioguanine" /><title>8.1.3 Antimetabolites: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5326-antimetabolites.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5326-antimetabolites.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP5326-antimetabolites.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
            Â 
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a></div><div id="pP"><div class="threecol_col1">â <a accesskey="[" href="PHP5323-mitoxantrone.htm" title="Previous: MITOXANTRONE">Previous page</a></div><div class="threecol_col2">Â </div><div class="threecol_col3"><a accesskey="]" href="PHP5360-azacitidine.htm" title="Next: AZACITIDINE">Next page</a> âº</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1><span>8.1.3 </span>Antimetabolites</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p>Antimetabolites are incorporated into new nuclear material or combine irreversibly with cellular enzymes, preventing normal cellular division.</p><p id="PHP5327"><strong>Methotrexate </strong>inhibits the enzyme dihydrofolate reductase, essential for the synthesis of purines and pyrimidines. It is given by mouth, intravenously, intramuscularly, or intrathecally.</p><p>Methotrexate is used as maintenance therapy for childhood acute lymphoblastic leukaemia. Other uses include choriocarcinoma, non-Hodgkin's lymphoma, and a number of solid tumours. Intrathecal methotrexate is used in the CNS prophylaxis of childhood acute lymphoblastic leukaemia, and as a therapy for established meningeal cancer or lymphoma.</p><p>Methotrexate causes myelosuppression, mucositis, and rarely pneumonitis. It is <strong>contra-indicated </strong>in significant renal impairment because it is excreted primarily by the kidney. It is also contra-indicated in patients with severe hepatic impairment. It should also be <strong>avoided</strong> in the presence of significant pleural effusion or ascites because it can accumulate in these fluids, and its subsequent return to the circulation may cause myelosuppression. Systemic toxicity may follow intrathecal administration and blood counts should be carefully monitored.</p><p>Folinic acid (<a title=" Cytotoxic drugs" href="PHP5180-cytotoxic-drugs.htm">section 8.1</a>) following methotrexate administration helps to prevent methotrexate-induced mucositis or myelosuppression.</p><p id="PHP5331"><strong>Capecitabine</strong>, which is metabolised to fluorouracil, is given by mouth. It is licensed as monotherapy or combination therapy for adjuvant treatment of advanced colon cancer following surgery, for monotherapy or combination therapy of metastatic colorectal cancer, and for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Capecitabine is also licensed for second-line treatment of locally advanced or metastatic breast cancer either in combination with docetaxel (where previous therapy included an anthracycline) or alone (after failure of a taxane and anthracycline regimen or where further anthracycline treatment is not indicated). For the role of capecitabine in the treatment of breast cancer, see <a title="BNF:sub-sub-section: Breast cancer" href="PHP5747-breast-cancer.htm">section 8.3.4.1</a>.</p><div id="PHP5332" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (April 2006)</h3><p>Capecitabine alone <em>or</em> oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes' C) colon cancer.</p><p><a href="http://www.nice.org.uk/TA100">www.nice.org.uk/TA100</a></p></div><div id="PHP5333" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Capecitabine and tegafur with uracil for metastatic colorectal cancer (May 2003)</h3><p>Capecitabine or tegafur with uracil [now discontinued] (in combination with folinic acid) is an option for the first-line treatment of metastatic colorectal cancer.</p><p><a href="http://www.nice.org.uk/TA61">www.nice.org.uk/TA61</a></p></div><div class="cI" id="PHP19211"><p class="cAE">NICE guidance</p><h3 class="cT">Capecitabine for the treatment of advanced gastric cancer (July 2010)</h3><p>Capecitabine in combination with a platinum-based regimen is recommended for the first-line treatment of inoperable advanced gastric cancer.</p><p><a href="http://www.nice.org.uk/TA191">www.nice.org.uk/TA191</a></p></div><p id="PHP5334"><strong>Cytarabine</strong> acts by interfering with pyrimidine synthesis. It is given subcutaneously, intravenously, or intrathecally. Its predominant use is in the induction of remission of acute myeloblastic leukaemia. It is a potent myelosuppressant and requires careful haematological monitoring. A liposomal formulation of cytarabine for intrathecal use is licensed for lymphomatous meningitis.</p><p id="PHP5336"><strong>Fludarabine</strong> is licensed for the initial treatment of advanced B-cell chronic lymphocytic leukaemia (CLL) or after first-line treatment in patients with sufficient bone-marrow reserves; it is usually given by mouth, but can be given by intravenous injection or infusion. Fludarabine is well tolerated but it does cause myelosuppression, which may be cumulative. Immunosuppression is also common (see panel on cladribine and fludarabine below), and co-trimoxazole is used to prevent pneumocystis infection. Immune-mediated haemolytic anaemia, thrombocytopenia, and neutropenia are less common side-effects.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (October 2006) that fludarabine is accepted for restricted use for the treatment of B-cell chronic lymphocytic leukaemia (CLL) in patients with sufficient bone marrow reserves. First-line treatment should only be initiated in patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease-related symptoms or evidence of progressive disease.</p><div id="PHP19185" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (February 2007)</h3><p>Fludarabine monotherapy, is <strong>not</strong> recommended for the first-line treatment of chronic lymphocytic leukaemia.</p><p><a href="http://www.nice.org.uk/TA29">www.nice.org.uk/TA29</a></p><p><a href="http://www.nice.org.uk/TA119">www.nice.org.uk/TA119</a></p></div><p id="PHP5338"><strong>Cladribine</strong> is given by intravenous infusion for the treatment of hairy cell leukaemia. It is also given for chronic lymphocytic leukaemia in patients who have failed to respond to standard regimens containing an alkylating agent. Cladribine produces severe myelosuppression, with neutropenia, anaemia, and thrombocytopenia; haemolytic anaemia has also been reported. High doses of cladribine have been associated with acute renal failure and severe neurotoxicity.</p><div class="cI" id="PHP5339"><p><strong>Cladribine</strong> and <strong>fludarabine</strong> have a potent and prolonged immunosuppresive effect. Patients treated with cladribine or fludarabine are more prone to serious bacterial, opportunistic fungal, and viral infections, and prophylactic therapy is recommended in those at risk. To prevent potentially fatal transfusion-related graft-versus-host reaction, only irradiated blood products should be administered. Prescribers should consult specialist literature when using highly immunosuppressive drugs.</p></div><p id="PHP5342"><strong>Clofarabine</strong> is licensed for the treatment of acute lymphoblastic leukaemia in patients aged 1 to 21 years who have relapsed or are refractory after receiving at least two previous regimens. It is given by intravenous infusion.</p><p id="PHP5343"><strong>Nelarabine</strong> is licensed for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma in patients who have relapsed or who are refractory after receiving at least two previous regimens. It is given by intravenous infusion. Neurotoxicity is common with nelarabine and close monitoring for neurological adverse events is strongly recommendedâdiscontinue if neurotoxicity occurs.</p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (March 2008) that the use of nelarabine (<em>Atriance</em>Â®) within NHS Scotland is restricted to bridging treatment before stem cell transplantation.</p><p id="PHP5344"><strong>Gemcitabine</strong> is used intravenously; it is given alone for elderly patients or for palliative treatment, or with cisplatin as first-line treatment for locally advanced or metastatic non-small cell lung cancer. It is also used in the treatment of locally advanced or metastatic pancreatic cancer (see <a title="target-block: Gemcitabine (NICE guidance Pancreatic cancer)" href="PHP5326-antimetabolites.htm#PHP5347">NICE guidance</a> below). Combined with cisplatin, gemcitabine is also licensed for the treatment of advanced bladder cancer. Combined with carboplatin, gemcitabine is licensed for the treatment of locally advanced or metastatic epithelial ovarian cancer which has relapsed after a recurrence-free interval of at least 6 months following previous platinum-based therapy. Combined with paclitaxel, gemcitabine is also licensed for the treatment of metastatic breast cancer which has relapsed after previous chemotherapy including an anthracycline (see <a title="target-block: Gemcitabine (NICE guidance breast cancer)" href="PHP5326-antimetabolites.htm#PHP5346">NICE guidance</a> below). Gemcitabine is generally well tolerated but it can cause mild gastro-intestinal side-effects, musculoskeletal pain, influenza-like symptoms and rashes; renal impairment and pulmonary toxicity have also been reported. Haemolytic uraemic syndrome has been reported rarely and gemcitabine should be discontinued if signs of microangiopathic haemolytic anaemia occur.</p><p>The <em>Scottish Medicines Consortium</em> has advised (November 2006) that gemcitabine is accepted for restricted use for the treatment of metastatic breast cancer, which has relapsed following previous chemotherapy including an anthracycline (unless contra-indicated).</p><div id="PHP5346" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Gemcitabine for the treatment of metastatic breast cancer (January 2007)</h3><p>Gemcitabine, in combination with paclitaxel, is an option for the treatment of metastatic breast cancer <strong>only</strong> when docetaxel monotherapy or docetaxel plus capecitabine are also considered appropriate.</p><p><a href="http://www.nice.org.uk/TA116">www.nice.org.uk/TA116</a></p></div><div id="PHP5347" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Gemcitabine for the treatment of pancreatic cancer (May 2001)</h3><p>Gemcitabine is an option for first-line chemotherapy for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky score of at least 50 [Karnofsky score is a measure of the ability to perform ordinary tasks].</p><p>Gemcitabine is not recommended for patients who can have potentially curative surgery. There is insufficient evidence about its use for second-line treatment of pancreatic adenocarcinoma.</p><p><a href="http://www.nice.org.uk/TA25">www.nice.org.uk/TA25</a></p></div><p id="PHP5348"><strong>Fluorouracil</strong> is used to treat a number of solid tumours, including gastro-intestinal tract cancers and breast cancer. It is commonly used with folinic acid in advanced colorectal cancer. It may also be used topically for certain malignant and pre-malignant skin lesions. Toxicity is unusual, but may include myelosuppression, mucositis, and rarely a cerebellar syndrome. On prolonged infusion, a desquamative handâfoot syndrome may occur.</p><p id="PHP5350"><strong>Pemetrexed</strong> inhibits thymidylate transferase and other folate-dependent enzymes. It is licensed for use with cisplatin for the treatment of unresectable malignant pleural mesothelioma which has not previously been treated with chemotherapy (see <a title="target-block: Pemetrexed NICE Guidance pleural mesothelioma" href="PHP5326-antimetabolites.htm#PHP5351">NICE guidance</a>, below). Pemetrexed is also licensed for use with cisplatin for the first-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see <a title="BNF:target-block: pemetrexed nice 2009" href="PHP5326-antimetabolites.htm#PHP5352">NICE guidance</a>, below), and as monotherapy for its second-line treatment (but see <a title="target-block: Pemtrexed NICE guidance non-small-cell lung cancer" href="PHP5326-antimetabolites.htm#PHP5353">NICE guidance</a>, below). It is also licensed as monotherapy for maintenance treatment in locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following platinum-based chemotherapy. Pemetrexed is given by intravenous infusion.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (July 2005) that pemetrexed (<em>AlimtaÂ®</em>) in combination with cisplatin is accepted for restricted use within NHS Scotland for previously untreated patients with stage III/IV unresectable malignant pleural mesothelioma.</p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (January 2010) that pemetrexed (<em>Alimta</em>Â®) is accepted for restricted use within NHS Scotland in combination with cisplatin for the first-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology; it is restricted to patients in whom the histology of the tumour has been confirmed as adenocarcinoma or large cell carcinoma.</p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (August 2008) that pemetrexed (<em>Alimta</em>Â®) is accepted for restricted use within NHS Scotland as monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer without predominantly squamous cell histology; it is restricted for use in patients with good performance status who would otherwise be eligible for docetaxel treatment.</p><div id="PHP5351" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008)</h3><p>Pemetrexed is an option for the treatment of malignant pleural mesothelioma only in patients who have a WHO performance status of 0 or 1 [WHO performance status is a measure of the ability to perform ordinary tasks], who are considered to have advanced disease and for whom surgical resection is considered inappropriate.</p><p><a href="http://www.nice.org.uk/TA135">www.nice.org.uk/TA135</a></p></div><div id="PHP5352" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Pemetrexed for the first-line treatment of non-small cell lung cancer (September 2009)</h3><p>Pemetrexed, in combination with cisplatin, is an option for the first-line treatment of locally advanced or metastatic non-small cell lung cancer only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.</p><p><a href="http://www.nice.org.uk/TA181">www.nice.org.uk/TA181</a></p></div><div id="PHP5353" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Pemetrexed for the treatment of non-small cell lung cancer (August 2007)</h3><p>Pemetrexed is <strong>not</strong> recommended for the treatment of locally advanced or metastatic non-small cell lung cancer which has previously been treated with chemotherapy.</p><p><a href="http://www.nice.org.uk/TA124">www.nice.org.uk/TA124</a></p></div><div id="PHP19186" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Pemetrexed for the treatment of non-small cell lung cancer (June 2010)</h3><p>Pemetrexed is an option for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following combination therapy of a platinum compound with either gemcitabine, paclitaxel, or docetaxel.</p><p><a href="http://www.nice.org.uk/TA190">www.nice.org.uk/TA190</a></p></div><p id="PHP5354"><strong>Raltitrexed</strong>, a thymidylate synthase inhibitor, is given intravenously for palliation of advanced colorectal cancer when fluorouracil and folinic acid cannot be used. It is probably of similar efficacy to fluorouracil. Raltitrexed is generally well tolerated, but can cause marked myelosuppression and gastro-intestinal side-effects.</p><div class="cI"><h3 class="cT">NICE guidance (irinotecan, oxaliplatin and raltitrexed for advanced colorectal cancer)</h3><p> See <a title="target-block: NICE: irinotecan" href="PHP5487-platinum-compounds.htm#PHP5494">Platinum Compounds</a></p></div><p id="PHP5355"><strong>Mercaptopurine</strong> is used as maintenance therapy for the acute leukaemias and in the management of ulcerative colitis and Crohn's disease (<a title="BNF:monograph: MERCAPTOPURINE" href="PHP531-mercaptopurine.htm">section 1.5.3</a>). Azathioprine, which is metabolised to mercaptopurine, is generally used as an immunosuppressant (<a title=" Antiproliferative immunosuppressants" href="PHP5598-antiproliferative-immunosuppressants.htm">section 8.2.1</a> and <a title="sub-section: Drugs which suppress the rheumatic disease process" href="PHP6554-drugs-that-suppress-the-rheumatic-disease-process.htm">section 10.1.3</a>). The dose of both drugs should be reduced if the patient is receiving allopurinol since it interferes with their metabolism.</p><p id="PHP5357"><strong>Tegafur</strong> is a prodrug of fluorouracil. Tegafur in combination with gimeracil and oteracil is given by mouth; gimeracil inhibits the degradation of fluorouracil and oteracil decreases the activity of fluorouracil in normal gastrointestinal mucosa. Tegafur in combination with gimeracil and oteracil is licensed for the treatment of advanced gastric cancer when used in combination with cisplatin. </p><p id="PHP5358"><strong>Tioguanine</strong> is given by mouth for the treatment of acute leukaemias and chronic myeloid leukaemia. It can be given at various stages of treatment in short-term cycles. Tioguanine has a lower incidence of gastro-intestinal side-effects than mercaptopurine. Long-term therapy is no longer recommended because of the high risk of liver toxicity; treatment with tioguanine should be discontinued if liver toxicity develops.</p><p id="PHP5359"><strong>Azacitidine</strong> is a pyrimidine analogue that is given by subcutaneous injection. It is used in the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia, in adults who are not eligible for haemotopoietic stem cell transplantation.</p><div id="PHP19187" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (March 2011)</h3><p>Azacitidine is recommended in adults who are not eligible for haemotopoietic stem cell transplantation as an option for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia, or acute myeloid leukaemia.</p><p><a href="http://www.nice.org.uk/TA218">www.nice.org.uk/TA218</a></p></div><p id="PHP18906"><strong>Decitabine</strong> is a pyrimidine analogue and is licensed for the treatment of newly diagnosed acute myeloid leukaemia in patients over 65 years who are not candidates for standard induction chemotherapy.</p></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5360-azacitidine"><a href="PHP5360-azacitidine.htm" title="AZACITIDINE">AZACITIDINE</a></li><li id="_PHP5362-capecitabine"><a href="PHP5362-capecitabine.htm" title="CAPECITABINE">CAPECITABINE</a></li><li id="_PHP5364-cladribine"><a href="PHP5364-cladribine.htm" title="CLADRIBINE">CLADRIBINE</a></li><li id="_PHP5367-clofarabine"><a href="PHP5367-clofarabine.htm" title="CLOFARABINE">CLOFARABINE</a></li><li id="_PHP5369-cytarabine"><a href="PHP5369-cytarabine.htm" title="CYTARABINE">CYTARABINE</a></li><li id="_PHP18896-decitabine"><a href="PHP18896-decitabine.htm" title="DECITABINE">DECITABINE</a></li><li id="_PHP5373-fludarabine-phosphate"><a href="PHP5373-fludarabine-phosphate.htm" title="FLUDARABINE PHOSPHATE">FLUDARABINE PHOSPHATE</a></li><li id="_PHP5376-fluorouracil"><a href="PHP5376-fluorouracil.htm" title="FLUOROURACIL">FLUOROURACIL</a></li><li id="_PHP5378-gemcitabine"><a href="PHP5378-gemcitabine.htm" title="GEMCITABINE">GEMCITABINE</a></li><li id="_PHP5381-mercaptopurine"><a href="PHP5381-mercaptopurine.htm" title="MERCAPTOPURINE">MERCAPTOPURINE</a></li><li id="_PHP5385-methotrexate"><a href="PHP5385-methotrexate.htm" title="METHOTREXATE">METHOTREXATE</a></li><li id="_PHP5388-nelarabine"><a href="PHP5388-nelarabine.htm" title="NELARABINE">NELARABINE</a></li><li id="_PHP5390-pemetrexed"><a href="PHP5390-pemetrexed.htm" title="PEMETREXED">PEMETREXED</a></li><li id="_PHP5392-raltitrexed"><a href="PHP5392-raltitrexed.htm" title="RALTITREXED">RALTITREXED</a></li><li id="_PHP18400-tegafur-with-gimeracil-and-oteracil"><a href="PHP18400-tegafur-with-gimeracil-and-oteracil.htm" title="TEGAFUR WITH GIMERACIL AND OTERACIL">TEGAFUR WITH GIMERACIL AND OTERACIL</a></li><li id="_PHP5397-tioguanine"><a href="PHP5397-tioguanine.htm" title="TIOGUANINE">TIOGUANINE</a></li></ul></div><?highlighter off?><div id="pE">â <a accesskey="[" href="PHP5323-mitoxantrone.htm">Previous: MITOXANTRONE</a> | <a class="top" href="PHP5326-antimetabolites.htm#">Top</a> | <a accesskey="]" href="PHP5360-azacitidine.htm">Next: AZACITIDINE</a> âº</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright Â© BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete Â© The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>